3-V Biosciences Presents Positive Preclinical Data On HCV Product Candidates Targeting FASN At The American Association For The Study Of Liver Disease Annual Meeting 2012
BCC Partners on behalf of 3-V Biosciences, Inc. Karen L. Bergman 650-575-1509 firstname.lastname@example.org
Michelle Corral 415-794-8662 email@example.com
SOURCE 3-V Biosciences, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts